Roche Competitors

RHHBF Stock

USD 285.76 9.24 3.13%

Roche Holding AG competes with Sanofi ADR, Bristol Myers, AstraZeneca PLC, Gilead Sciences, and Novartis; as well as few others. The company classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. Analyzing Roche Holding competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Roche Holding to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Roche Holding Correlation with its peers.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Roche Holding competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
291.77	295.00	298.23

Details

Intrinsic

Valuation

Low	Real	High
256.33	259.56	324.50

Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Roche Holding. Your research has to be compared to or analyzed against Roche Holding's peers to derive any actionable benefits. When done correctly, Roche Holding's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Roche Holding AG.

Roche Holding Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Roche Holding and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Roche and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Roche Holding AG does not affect the price movement of the other competitor.

	SNY	BMY	AZN	GILD	NVS
SNY		-0.92	0.9	-0.81	0.94	SNY
BMY	-0.92		-0.85	0.82	-0.86	BMY
AZN	0.9	-0.85		-0.84	0.92	AZN
GILD	-0.81	0.82	-0.84		-0.79	GILD
NVS	0.94	-0.86	0.92	-0.79		NVS
	SNY	BMY	AZN	GILD	NVS

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

NVS	+ 0.94	SNY
NVS	+ 0.92	AZN
AZN	+ 0.9	SNY
GILD	+ 0.82	BMY

High negative correlations

BMY	- 0.92	SNY
NVS	- 0.86	BMY
AZN	- 0.85	BMY
GILD	- 0.84	AZN
GILD	- 0.81	SNY
NVS	- 0.79	GILD

Risk-Adjusted Indicators

There is a big difference between Roche OTC Stock performing well and Roche Holding OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Roche Holding's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
SNY	0.82	(0.30)	0.00	(3.05)	0.00	0.00	1.13	(2.08)	7.81
BMY	1.31	0.23	0.11	1.46	1.29	(1.48)	2.23	(2.09)	14.39
AZN	1.04	(0.25)	0.00	2.11	0.00	0.00	1.32	(2.78)	8.50
GILD	0.92	0.12	0.05	0.33	1.19	(0.89)	1.94	(1.82)	10.79
NVS	0.67	(0.26)	0.00	(5.93)	0.00	0.00	1.12	(1.52)	6.05

Unable to evaluate fundamental data of [SNY, BMY, AZN, GILD, NVS] at this time. Please try again later

All Fundamental Data

Roche Holding Competitive Analysis

The better you understand Roche Holding competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Roche Holding's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Roche Holding's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	RHHBF	SNY	BMY	AZN	GILD	NVS
	3.13 285.76 Roche	0.40 46.80 Sanofi	0.89 55.78 Bristol	0.54 66.58 AstraZeneca	0.27 91.86 Gilead	0.23 98.36 Novartis
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Very Weak	Very Weak	OK	Very Weak	OK	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Very Small	Low	Low	Very Low	Very Low
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Under Valued	Under Valued	Fairly Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Strong Buy	Buy	Strong Buy	Strong Buy	Buy
Trade Advice (90 Days Macroaxis Advice)	Strong Sell	Hold	Strong Hold	Cautious Hold	Buy	Hold
Current Ratio	1.11 X	1.30 X	1.42 X	0.81 X	1.43 X	1.31 X
Net Asset	92.32 B	126.46 B	95.16 B	101.12 B	62.12 B	99.94 B
Profit Margin	0.19 %	0.09 %	(0.15) %	0.13 %	0 %	0.35 %
EBITDA	22.26 B	12.6 B	19.37 B	13.42 B	7.61 B	18.29 B
Operating Margin	0.32 %	0.29 %	0.18 %	0.20 %	0.42 %	0.33 %
Current Valuation	287.91 B	138.38 B	158.2 B	235.41 B	133.34 B	217.44 B
Price To Book	11.61 X	1.54 X	6.66 X	5.10 X	6.23 X	4.55 X
Retained Earnings	25.51 B	67.5 B	28.77 B	4.52 B	16.3 B	49.65 B
Current Asset	26.61 B	24.93 B	10.41 B	16.01 B	1.18 B	22.84 B
Five Year Return	3.23 %	3.85 %	2.96 %	2.99 %	3.76 %	3.53 %
Beta	0.19	0.45	0.44	0.18	0.19	0.51
Number Of Employees	103.61 K	86.09 K	34.1 K	89.9 K	18 K	76.06 K
Shares Outstanding	106.69 M	2.51 B	2.03 B	3.1 B	1.25 B	2 B
Cash Flow From Operations	20.98 B	10.26 B	13.86 B	10.35 B	8.01 B	14.46 B
Annual Yield	0.03 %	0.04 %	0.04 %	0.02 %	0.03 %	0.04 %
Total Debt	16.08 B	18.42 B	41.46 B	28.62 B	24.99 B	26.35 B
Return On Equity	0.45	0.0582	-0.31	0.17	0.0056	0.29
Z Score	9.0	N/A	N/A	N/A	N/A	N/A
Return On Asset	0.15	0.0416	0.0607	0.085	0.12	0.11
Book Value Per Share	35.03 X	58.10 X	8.45 X	26.27 X	14.83 X	21.67 X
Number Of Shares Shorted	N/A	4.53 M	25.6 M	7.4 M	23.41 M	4.49 M
Current Liabilities	24.46 B	16.82 B	8.02 B	14.87 B	104.89 M	23.71 B
Total Asset	92.32 B	126.46 B	95.16 B	101.12 B	62.12 B	99.94 B
Debt To Equity	1.00 %	0.30 %	1.32 %	0.89 %	1.30 %	0.47 %
Target Price	423.65	63.49	60.58	88.01	98.92	114.03
Last Dividend Paid	9.5	N/A	2.4	2.97	3.06	3.92
Short Ratio	N/A	2.00 X	2.16 X	0.92 X	3.21 X	3.27 X
Shares Owned By Institutions	8.56 %	11.43 %	78.48 %	16.76 %	88.40 %	6.74 %
Market Capitalization	246.23 B	121.39 B	114.9 B	207.76 B	115.13 B	199.17 B
Price To Earning	21.63 X	7.78 X	24.88 X	103.39 X	359.42 X	9.22 X
Price To Earnings To Growth	4.18 X	0.73 X	1.94 X	0.72 X	0.53 X	2.93 X
Price To Sales	4.11 X	2.51 X	2.42 X	4.06 X	4.07 X	3.99 X
Net Income	13.93 B	5.4 B	8.04 B	6.9 B	5.61 B	8.57 B
Earnings Per Share	19.18 X	1.88 X	(3.55) X	2.08 X	0.09 X	5.73 X
Shares Owned By Insiders	75.31 %	N/A	0.11 %	N/A	0.11 %	N/A
Revenue	62.8 B	46.03 B	45.01 B	45.81 B	27.12 B	46.66 B
Working Capital	2.16 B	6.46 B	9.51 B	(5.49 B)	4.8 B	4.09 B
Cash And Equivalents	6.81 B	6.9 B	9.12 B	4.52 B	6.14 B	4.64 B
Cash Per Share	8.50 X	2.76 X	6.21 X	1.46 X	4.90 X	8.84 X
Gross Profit	47.83 B	31.7 B	36.38 B	35.73 B	21.62 B	36.74 B
Day Typical Price	285.76	46.76	55.73	66.47	91.04	98.26
Accumulation Distribution	N/A	52960.42	223535.0	53922.52	241489.0	8514.66
Daily Balance Of Power	(9,223,372,036,855)	(0.26)	(0.37)	(0.65)	0.0845	(0.34)
Period Momentum Indicator	(9.24)	(0.19)	(0.50)	(0.36)	0.25	(0.23)
Rate Of Daily Change	0.97	1.0	0.99	0.99	1.0	1.0
Day Median Price	285.76	46.74	55.71	66.41	90.63	98.21
Price Action Indicator	(4.62)	(0.04)	(0.18)	(0.01)	1.35	0.035
Coefficient Of Variation	(3,026)	(397.94)	773.54	(591.66)	774.91	(398.44)
Mean Deviation	2.07	0.8205	1.31	1.04	0.9206	0.6727
Jensen Alpha	(0.11)	(0.30)	0.2306	(0.25)	0.1247	(0.26)
Total Risk Alpha	(0.51)	(0.44)	(0.0001)	(0.44)	(0)	(0.37)
Sortino Ratio	N/A	N/A	0.1054	N/A	0.0535	N/A
Downside Variance	N/A	N/A	2.18	N/A	2.28	N/A
Standard Deviation	3.19	1.14	1.98	1.46	1.4	0.9617
Kurtosis	1.19	4.07	10.81	7.07	7.4	4.86
Potential Upside	5.59	1.13	2.23	1.32	1.94	1.12
Treynor Ratio	1.28	(3.05)	1.46	2.11	0.3337	(5.93)
Maximum Drawdown	16.69	7.81	14.39	8.5	10.79	6.05
Variance	10.2	1.29	3.91	2.14	1.96	0.9249
Market Risk Adjusted Performance	1.29	(3.04)	1.47	2.12	0.3437	(5.92)
Risk Adjusted Performance	(0.02)	(0.18)	0.1001	(0.12)	0.0984	(0.18)
Skewness	(0.03)	0.5101	2.26	(1.98)	0.9847	(1.31)
Semi Deviation	N/A	N/A	1.29	N/A	1.19	N/A
Information Ratio	(0.06)	(0.34)	0.0787	(0.24)	0.0576	(0.36)
Value At Risk	(5.97)	(2.08)	(2.09)	(2.78)	(1.82)	(1.52)
Expected Short fall	N/A	N/A	(1.48)	N/A	(0.89)	N/A
Downside Deviation	N/A	N/A	1.48	N/A	1.51	N/A
Semi Variance	N/A	N/A	1.65	N/A	1.41	N/A

Roche Holding Competition Performance Charts

Five steps to successful analysis of Roche Holding Competition

Roche Holding's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Roche Holding AG in relation to its competition. Roche Holding's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Roche Holding in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Roche Holding's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Roche Holding AG, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Roche Holding position

In addition to having Roche Holding in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Chemicals Thematic Idea Now

Chemicals

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Chemicals theme has 61 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Theme or any other thematic opportunities.

View All Next

Launch

Other Information on Investing in Roche OTC Stock

Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC